Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of T-cell activity in alopecia areata: recent developments and new directions.
Passeron T, King B, Seneschal J, Steinhoff M, Jabbari A, Ohyama M, Tobin DJ, Randhawa S, Winkler A, Telliez JB, Martin D, Lejeune A. Passeron T, et al. Among authors: telliez jb. Front Immunol. 2023 Nov 6;14:1243556. doi: 10.3389/fimmu.2023.1243556. eCollection 2023. Front Immunol. 2023. PMID: 38022501 Free PMC article. Review.
Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open-Label, Phase 1 Study.
Martin DA, Telliez JB, Pleasic-Williams S, Zhang Y, Tierney B, Blatnik M, Gale JD, Banfield C, Zhou Y, Lejeune A, Zwillich SH, Stevens E, Tiwari N, Kieras E, Karanam A. Martin DA, et al. Among authors: telliez jb. J Clin Pharmacol. 2024 Jan;64(1):67-79. doi: 10.1002/jcph.2347. Epub 2023 Sep 29. J Clin Pharmacol. 2024. PMID: 37691236 Clinical Trial.
JAK inhibitor selectivity: new opportunities, better drugs?
Virtanen A, Spinelli FR, Telliez JB, O'Shea JJ, Silvennoinen O, Gadina M. Virtanen A, et al. Among authors: telliez jb. Nat Rev Rheumatol. 2024 Oct;20(10):649-665. doi: 10.1038/s41584-024-01153-1. Epub 2024 Sep 9. Nat Rev Rheumatol. 2024. PMID: 39251770 Review.
Editorial: JAK inhibition in autoimmune and inflammatory diseases.
Telliez JB, Gadina M, Ghoreschi K, Silvennoinen O, Spinelli FR. Telliez JB, et al. Front Immunol. 2022 Dec 28;13:1120281. doi: 10.3389/fimmu.2022.1120281. eCollection 2022. Front Immunol. 2022. PMID: 36643918 Free PMC article. No abstract available.
The advantages of describing covalent inhibitor in vitro potencies by IC50 at a fixed time point. IC50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization.
Thorarensen A, Balbo P, Banker ME, Czerwinski RM, Kuhn M, Maurer TS, Telliez JB, Vincent F, Wittwer AJ. Thorarensen A, et al. Among authors: telliez jb. Bioorg Med Chem. 2021 Jan 1;29:115865. doi: 10.1016/j.bmc.2020.115865. Epub 2020 Nov 18. Bioorg Med Chem. 2021. PMID: 33285410
PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.
Xu H, Jesson MI, Seneviratne UI, Lin TH, Sharif MN, Xue L, Nguyen C, Everley RA, Trujillo JI, Johnson DS, Point GR, Thorarensen A, Kilty I, Telliez JB. Xu H, et al. Among authors: telliez jb. ACS Chem Biol. 2019 Jun 21;14(6):1235-1242. doi: 10.1021/acschembio.9b00188. Epub 2019 May 22. ACS Chem Biol. 2019. PMID: 31082193
Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.
Casimiro-Garcia A, Trujillo JI, Vajdos F, Juba B, Banker ME, Aulabaugh A, Balbo P, Bauman J, Chrencik J, Coe JW, Czerwinski R, Dowty M, Knafels JD, Kwon S, Leung L, Liang S, Robinson RP, Telliez JB, Unwalla R, Yang X, Thorarensen A. Casimiro-Garcia A, et al. Among authors: telliez jb. J Med Chem. 2018 Dec 13;61(23):10665-10699. doi: 10.1021/acs.jmedchem.8b01308. Epub 2018 Nov 30. J Med Chem. 2018. PMID: 30423248
48 results